CDT EQUITY NEW DL-,0001

CDT Equity has approved a 1-for-10 reverse stock split effective Friday at 5:00 p.m. Eastern Time; trading is expected to resume on Monday on a split-adjusted basis under the ticker CDT. After the split, approximately 631,077 common shares will be outstanding and the stock will trade under the new CUSIP 20678X601. Fractional shares will not be issued; eligible shareholders will receive a cash payment, and holdings at depositary banks will be adjusted automatically. The stock currently trades around $0.35 near its 52-week low, with a market capitalization of about $1.71 million and a current ratio of 0.34. » More on de.investing.com

Canada has granted a patent for the use of AZD5904 in male infertility, completing patent approvals in all major pharmaceutical markets according to the company. CDT Equity views the decision as a strengthening of its intellectual property and as a basis for licensing and partner discussions; AZD5904 was licensed from AstraZeneca and already has a clinical safety package as well as preclinical validation data. The company notes that despite market opportunities estimated at $4.4 billion annually for male infertility, it has a very small market capitalization and a strained financial position. » More on de.investing.com

CDT Equity released results for the quarter ended 31.12.2025 and reported an EPS of −$943.76. For the full fiscal year, the company recorded a loss per share of −$1,177.89. In the prior-year quarter and year, EPS were −$1,590.00 and −$61,590.00, respectively. » More on finanzen.net